Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review

Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:


- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG Key Recent Developments

Apr 02,2020: Novartis terminates $1bn Sandoz US deal with Aurobindo
Apr 02,2020: Others : Novartis announces mutual agreement to terminate sale of Basel, April 2, 2020 Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement to sell the Sandoz US generic oral solids and dermatology
Mar 31,2020: Three institutions in US and UK secure grants for Covid-19 research
Mar 30,2020: Novartis gets positive CHMP opinion for Zolgensma and Cosentyx
Mar 30,2020: Global Nasal Drug Delivery Technology to 2025 - Featuring 3M, Aptargroup & Novartis International Among Others - ResearchAndMarkets.com

Key benefits of buying this profile include:


You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 


Section 1 - About the Company
Novartis AG - Key Facts
Novartis AG - Key Employees
Novartis AG - Key Employee Biographies
Novartis AG - Major Products and Services
Novartis AG - History
Novartis AG - Company Statement
Novartis AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Novartis AG - Business Description
Business Segment: Innovative Medicines
Overview
Performance
Key Stats
Business Segment: Sandoz
Overview
Performance
Key Stats
Geographical Segment: Asia/Africa/Australasia
Performance
Geographical Segment: Canada and Latin America
Target Markets
Geographical Segment: Europe
Performance
Geographical Segment: US
Performance
R&D Overview
Novartis AG - Corporate Strategy
Novartis AG - SWOT Analysis
SWOT Analysis - Overview
Novartis AG - Strengths
Novartis AG - Weaknesses
Novartis AG - Opportunities
Novartis AG - Threats
Novartis AG - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Novartis AG, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 02, 2020: Novartis terminates $1bn Sandoz US deal with Aurobindo
Mar 31, 2020: Three institutions in US and UK secure grants for Covid-19 research
Mar 30, 2020: Novartis gets positive CHMP opinion for Zolgensma and Cosentyx
Mar 27, 2020: Novartis partners with life sciences companies to fight Covid-19
Mar 26, 2020: Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
Mar 23, 2020: Novartis, Amneal, Apotex offer hydroxychloroquine for Covid-19
Mar 17, 2020: Novartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communities
Mar 10, 2020: Boehringer Ingelheim and Novartis Pharma recognized as the Best Places To Work for in Algeria in 2020
Mar 06, 2020: Orionis and Novartis enter drug discovery deal
Mar 03, 2020: EDCTP commits €21.9m to MMV-led malaria research consortium
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
 


List Of Tables


Novartis AG, Key Facts
Novartis AG, Key Employees
Novartis AG, Key Employee Biographies
Novartis AG, Major Products and Services
Novartis AG, History
Novartis AG, Subsidiaries
Novartis AG, Joint Venture
Novartis AG, Key Competitors
Novartis AG, Ratios based on current share price
Novartis AG, Annual Ratios
Novartis AG, Annual Ratios (Cont...1)
Novartis AG, Annual Ratios (Cont...2)
Novartis AG, Interim Ratios
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Novartis AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
 


List Of Figures


Novartis AG, Performance Chart (2015 - 2019)
Novartis AG, Ratio Charts
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
 


Respiratory Diseases Drugs Global Market Forecast To 2022 Including: Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations Covering: GlaxosmithKline Plc, AstraZeneca Plc, Merck & Co, Novartis AG, Johnson & Johnson

The respiratory diseases drugs market consists of sales of respiratory diseases drugs and related services by entities (organizations, sole traders and partnerships) that produce drugs to treat respiratory diseases such

USD 4000 View Report

Ophthalmology Drugs Global Market Forecast To 2022 Including: Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy) Covering: Novartis AG, F. Hoffmann-La Roche Ltd, Allergan Plc, Valeant Pharmaceuticals Intl Inc, Bayer AG

The ophthalmology drugs market consists of sales of ophthalmology drugs and related services by entities (organizations, sole traders and partnerships) that produce ophthalmology drugs to treat eye related diseases. This

USD 4000 View Report

Respiratory Diseases Drugs Global Market Forecast To 2022 Including: Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations Covering: GlaxosmithKline Plc, AstraZeneca Plc, Merck & Co, Novartis AG, Johnson & Johnson

The respiratory diseases drugs market consists of sales of respiratory diseases drugs and related services by entities (organizations, sole traders and partnerships) that produce drugs to treat respiratory diseases such

USD 4000 View Report

Ophthalmology Drugs Global Market Forecast To 2022 Including: Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy) Covering: Novartis AG, F. Hoffmann-La Roche Ltd, Allergan Plc, Valeant Pharmaceuticals Intl Inc, Bayer AG

The ophthalmology drugs market consists of sales of ophthalmology drugs and related services by entities (organizations, sole traders and partnerships) that produce ophthalmology drugs to treat eye related diseases. This

USD 4000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available